Auris Medical Holding AG (NASDAQ:EARS) shares traded down 4.2% on Tuesday . The company traded as low as $0.68 and last traded at $0.69. 555,928 shares were traded during mid-day trading, an increase of 70% from the average session volume of 327,863 shares. The stock had previously closed at $0.72.

A number of research analysts have recently weighed in on the company. Roth Capital restated a “buy” rating and issued a $5.00 target price on shares of Auris Medical Holding AG in a report on Saturday, July 1st. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, August 30th. Finally, ValuEngine lowered Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $3.25.

The company has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.76. The firm’s market cap is $30.77 million.

Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.09. Equities research analysts anticipate that Auris Medical Holding AG will post ($0.63) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the business. Virtu KCG Holdings LLC acquired a new position in shares of Auris Medical Holding AG in the second quarter worth about $101,000. Sabby Management LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $133,000. Perceptive Advisors LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $368,000. Finally, UBS Oconnor LLC acquired a new position in shares of Auris Medical Holding AG in the first quarter worth about $909,000. Institutional investors and hedge funds own 28.41% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/05/auris-medical-holding-ag-ears-trading-down-4-2.html.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.